Amgen

YTD

ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K.

CEO

Robert A. Bradway

CEORobert A. Bradway

Employees

31,500

Employees31,500

Headquarters

Thousand Oaks, California

HeadquartersThousand Oaks, California

Founded

1980

Founded1980

Employees

31,500

Employees31,500

AMGN Key Statistics

Market cap

198.80B

Market cap198.80B

Price-Earnings ratio

25.60

Price-Earnings ratio25.60

Dividend yield

2.66%

Dividend yield2.66%

Average volume

2.49M

Average volume2.49M

High today

$371.42

High today$371.42

Low today

$363.00

Low today$363.00

Open price

$363.85

Open price$363.85

Volume

865.41K

Volume865.41K

52 Week high

$391.29

52 Week high$391.29

52 Week low

$269.77

52 Week low$269.77

Stock Snapshot

As of today, Amgen(AMGN) shares are valued at $368.34. The company's market cap stands at 198.8B, with a P/E ratio of 25.60 and a dividend yield of 2.66%.

During the trading session on 2026-07-08, Amgen(AMGN) shares reached a daily high of $371.42 and a low of $363.00. At a current price of $368.34, the stock is +1.5% higher than the low and still -0.8% under the high.

Trading activity shows a volume of 865.41K, compared to an average daily volume of 2.49M.

The stock's 52-week range extends from a low of $269.77 to a high of $391.29.

AMGN News

TipRanks 6h

Amgen price target lowered to $333 from $340 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Amgen (AMGN) to $333 from $340 and keeps an Equal Weight rating on the shares. Biotech could benefit from broa...

The Motley Fool 20h

How Safe Is Amgen's Dividend? - The Motley Fool

...

Simply Wall St 3d

Amgen Could Be 45% Below Fair Value As Court Blocks Enbrel Price Cap

Amgen (AMGN) is back in focus after a federal judge blocked Colorado’s proposed 70% price cap on Enbrel, which removed an immediate regulatory threat to one of...

Analyst ratings

49%

of 35 ratings

Buy

40%

Hold

48.6%

Sell

11.4%

More AMGN News

The Motley Fool 4d

Alphabet Officially Joins the Dow. These 3 Dow Dividend Stocks Are Better Buys for July.

The Dow Jones Industrial Average looks different this month. Before trading opened on June 29, Alphabet (GOOGL 0.23%) (GOOG 0.48%) took Verizon Communications'...

Nasdaq 5d

Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug

Roche RHHBY reported positive results from the late-stage Krascendo 1 study evaluating experimental candidate, divarasib, in patients with previously treated KR...

TipRanks 6d

Amgen’s Rocatinlimab Asthma Trial Reaches Phase 2 Finish Line

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more c...

Simply Wall St 6d

Does Tavneos Retraction And Possible Withdrawal Reshape The Bull Case For Amgen?

The New England Journal of Medicine has retracted the pivotal Tavneos study and, following regulatory concerns over severe liver injuries, both the FDA and Euro...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.